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Fabry disease: Diagnosis and treatment. Fabry disease is an as renal glomerular and tubular cells, cardiac myocytes
X-linked lysosomal storage disorder that results from a defi- and valvular fibrocytes, epithelial cells of the cornea,
ciency of the enzyme -galactosidase A (-Gal A). The lack ganglion cells of the dorsal root and the autonomic ner-of -Gal A causes an intracellular accumulation of glycosphin-
vous system, as well as cortical and brain stem structures.golipids, mainly globotriaosyceramide (GL3). Affected organs
Lipid depositions are also seen in endothelial, perithelial,include, among others, the vascular endothelium, heart, brain,
and kidneys, leading to end-stage renal disease (ESRD). Since and smooth muscle cells of the vascular system [3].
Fabry disease cannot be cured at present, clinical management
is symptomatic. Enzyme replacement therapy (ERT) with re-
combinant -Gal A has been introduced as a new therapeutic SYMPTOMS AND CLINICAL COURSE
option for the treatment of Fabry patients.
The presenting symptoms of affected individuals andShort-term (one year) clinical studies have positively corre-
the clinical course of Fabry disease are highly variable.lated ERT with improvement of clinical symptoms and micro-
Acroparesthesia, with an onset in early childhood, con-vascular endothelial cell clearance. Treatment outcome con-
cerning severe organ manifestations such as proteinuria and stitutes one of the earliest and most debilitating symp-
renal function impairment, left ventricular hypertrophy, and toms and is often accompanied by fever, hypohidrosis,
heart failure in the long run has yet to be shown. In our studies and heat intolerance. Other characteristic features arewe used sensitive and noninvasive techniques such as ultrasound-
lenticular and corneal opacities, angiokeratoma, edema,based strain rate imaging and magnetic resonance imaging
and abdominal pain. During the third and fourth decade(MRI), combined with MR-spectroscopy (MR-S), for the quan-
tification of functional abnormalities at an early stage of the of life, Fabry disease is characterized by a progressive
disease and during long-term follow-up. Future issues should course and severe morbidity due to cardiac, renal, and
determine the appropriate timing to start therapy and how cerebrovascular involvement [4]. Renal disease is one of
children and heterozygous females should be managed. Given
the major causes of morbidity and mortality in Fabrythe diagnostic and therapeutic potential today, it is of impor-
patients [5]. In classically affected males, the first renaltance to identify patients at an early stage and to start thera-
peutic intervention before progression of organ damage is in- manifestations can be observed as proteinuria, micro-
evitable. hematuria, and lipiduria. With advancing age, most of
these patients show progressive renal failure. ESRD typi-
cally occurs in the third to fifth decade of life [5]. Myocar-
Fabry disease was first described more than 100 years dial involvement in patients with Fabry disease is well
ago because of its characteristic skin lesions, known as documented with concentric or asymmetrical left ventric-
angiokeratoma corporis diffusum universale [1, 2]. It is ular hypertrophy (LVH) [6, 7]. Clinical signs of cardiac
an inborn error of glycosphingolipid metabolism, which involvement typically occur late in the course of the
is due to a wide variety of mutations in the gene that disease and many patients die from heart failure [8, 9].
encodes the lysosomal enzyme -Gal A. The deficiency Further complications include conduction abnormalities
of -Gal A causes an incomplete metabolism and pro- with reduced PR-interval [10] and cardiac arrhythmias
[11]. Typical cerebrovascular symptoms in classic malegressive lysosomal accumulation of neutral glycosphin-
patients are vertigo, headache, diplopia, dysarthria, andgolipids, mainly globotriaosylceramide (GL3), in af-
hemiataxia. There is an elevated risk for transient isch-fected males and to a lesser extent in female carriers.
emic attacks, premature stroke, and dementia [12, 13].This process leads to damage to various cell types, such
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Table 1. Evaluation tests conducted on all patients recruited to theextremities, which occur in 80% to 90% of patients.
Wu¨rzburg outpatient center before start of enzyme replacement
In combination with hypohidrosis, heat intolerance, and therapy for Fabry disease
characteristic angiokeratomas, these patients are highly
Tests performedsusceptible for classic Fabry disease. Pathognomonic Medical history/physical examination
symptoms are corneal opacities (cornea verticillata) and Completion of brief pain inventory
Blood teststypical conjunctival involvement. The presumptive diag-
Total blood chemistry, full blood count, coagulation tests, CRPnosis based on the symptoms above is supported by a Blood group; Hepatitis B and C testing
positive family history. The clinical diagnosis must be -Gal A activity, genotyping
Cardiac testingconfirmed by assay of -GAL A activity in leukocytes
ECG, 24-hour ECG, exercise testingor plasma, and/or detection of GL3 deposition in tissue Echocardiography/strain rate imaging
biopsies, and should be followed by a molecular genetic Cardiac MRI, MRS
Kidney function testsanalysis. Taking pedigrees of newly diagnosed patients
Urine sedimentation testis worthwhile and may reveal more affected individuals. 24-hour proteinuria, creatinine clearance
GFR, by 99mTc-DTPA
Kidney biopsy (in selected patients)
Dermatologic testsESTABLISHING A DIAGNOSTIC AND
Photographic documentationTREATMENT CENTER FOR FABRY DISEASE
Skin biopsy
Sweat testIn March 2001, our institution launched an outpatient
Other testscenter for the diagnosis and treatment of Fabry disease.
Renal ultrasound
The objectives of the center are to raise awareness of Pulmonary function (spirometry)
Cranial MRIFabry disease, to identify patients with no previous diag-
Audio-visual testingnosis, and to make ERT accessible to all Fabry patients
Abbreviations are: CRP, C reactive protein; -Gal A, -galactosidase; ECG,with an indication for treatment. We seek to enroll suffi-
electrocardiography; MRI, magnetic resonance imaging; MRS, magnetic reso-
cient numbers of patients in this evaluation program to nance spectroscopy; GFR, glomerular filtration rate.
reveal efficacy and safety of ERT in clinical practice.
Subsequently, all patient data are anonymously entered
into the Internet-based international Fabry registry. The
clinical benefit. In addition to conventional echocardiog-majority of patients who have attended our center were
raphy, we have introduced ultrasound-based strain ratereferred by adult nephrologists or internists. All patients
imaging in the surveillance of regional LV function be-are provided with a confirmed diagnosis through deter-
fore and during ERT. This new technique has beenmination of-GAL A activity and/or genotyping. Indica-
shown to quantify regional changes in myocardial defor-tion for therapy is established and this may depend on
mation properties [14]. Myocardial strain measurementsage, sex, and severity of symptoms. Affected males are
have been validated both in correlative experimentalall considered to have an indication for therapy, but
sonomicrometry [15] and in clinical studies [16].females and children undergo further evaluation to de-
termine their suitability for treatment.
Magnetic resonance imaging (MRI) and
spectroscopy (MRS)
PATIENT EVALUATION PROGRAM MRI allows quantitative assessment of cardiac mor-
phology and function with high accuracy and objectivity,Due to the variety and variability of possible manifes-
as well as detection of inflammatory alterations in thetations, every patient with confirmed diagnosis of Fabry
myocardium, using contrast enhancement techniquesdisease undergoes a comprehensive clinical evaluation
[17, 18]. MRS offers the additional possibility to detectprogram before treatment is started (Table 1). This base-
fundamental metabolic derangements in cardiomyo-line set of data serves to determine advanced organ dam-
cytes, which allow detection of subclinical cardiac com-age and allows the benefits of ERT to be quantitated
mitment in different kinds of heart disease [19]. Forduring follow-up. To date, all patients who have under-
MRS, absolute concentrations of energy metabolites,gone the initial evaluation have agreed to participate.
such as adenosine triphosphate (ATP) and phosphocre-Parts of the program have been approved by the local
atine (PCr), are measured and an energetic index canethical committee and patients have given written con-
be determined [20].sent according to the principles of the declaration of
Helsinki.
Kidney function and biopsy
Echocardiography Kidney function in patients enrolled so far in clinical
trials has been well preserved [21, 22]. However, pre-To detect cardiac involvement at an early stage of the
disease, sensitive noninvasive imaging techniques are of treatment biopsies revealed that these patients had ex-
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Fig. 2. Electron micrograph showing the electron dense lipid deposi-
tions in the vascular endothelium (arrows) of a skin capillary from a
29-year-old male Fabry patient (magnification x 3000).
tensive drugs may delay progressive loss of renal func-
tion. Therapy of heart disease includes antiarrhythmic
drugs, artificial pacemakers, and coronary bypass graft-
ing in case of coronary heart disease. For patients with
chronic pain, the use of gabapentin, carbamazepin, or
phenytoin is recommended. New therapeutic approaches
for causal or specific treatment of Fabry disease, such
as substrate deprivation or gene therapy, are promising
but will not be available in the near future [23, 24].
A new specific treatment option that has reached the
stage of clinical use is ERT. After cloning the -GAL gene
[25] and making advances in molecular genetic techniques,
recombinant -GAL is now synthesized by geneticallyFig. 1. Typical angiokeratomas in Fabry disease. Characteristic dark-
red to blue-dark angiectases, typically found between the umbilicus and engineered cell lines and available in two enzyme for-
thigh. The lesions range in size from pinpoint to several millimeters.
mulations. Safety and efficacy of the two enzyme prepa-
rations have been tested in preclinical studies [26, 27].
Subsequently, the enzymes were evaluated in two ran-tensive renal deposition of GL3 at study entry. This
domized, double blind, and placebo-controlled trials withexperience suggests that serum creatinine may not be
26 patients (agalsidase alpha) and 52 patients (agalsidasean adequate parameter to investigate the benefit of ERT
beta), respectively. Agalsidase alpha was given intrave-in moderate to severe renal disease. Renal function is
nously every 14 days at a dose of 0.2 mg/kg/body weightestimated by measurement of the glomerular filtration
for 24 weeks [21], and a significant reduction of neuro-rate (GFR), as well as by 24-hour creatinine clearance,
pathic pain (primary end point) was demonstrated. Ini-or even more accurately by techniques using nuclear
tial kidney function was well preserved and remainedtrace material (99mTc-DTPA). Additional information
stable in the treatment group, whereas a deteriorationcan be obtained by measuring 24-hour albuminuria/pro-
teinuria. Kidney biopsy should be performed whenever of GFR was found in the placebo group. The second study
patients are enrolled in a controlled clinical program. In used agalsidase beta at a dose of 1 mg/kg/body weight
the absence of significant urinary protein excretion, and [22]. Primary end point was the clearance of interstitial
when the extent of kidney damage is difficult to deter- microvascular GL3 deposits in renal biopsy specimens.
mine, the performance of a renal biopsy may provide After 20 weeks of ERT, there was a significant reduction
helpful information. of depositions in the treatment compared with the pla-
cebo group. This was also noted in heart and skin speci-
TREATMENT OPTIONS mens. Initial renal function (GFR and serum creatinine)
was normal and remained stable throughout the studyAt present, treatment of Fabry disease is limited to
symptom management. ACE inhibitors and antihyper- in both groups.
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